Crestline Management LP Sells 15,795 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Crestline Management LP reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 64.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,625 shares of the specialty pharmaceutical company's stock after selling 15,795 shares during the quarter. Crestline Management LP's holdings in Jazz Pharmaceuticals were worth $1,062,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of JAZZ. Moloney Securities Asset Management LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter valued at $464,000. Hennion & Walsh Asset Management Inc. grew its stake in Jazz Pharmaceuticals by 13.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock valued at $4,420,000 after acquiring an additional 4,332 shares in the last quarter. BTC Capital Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 9.4% in the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock valued at $6,115,000 after purchasing an additional 4,271 shares during the period. Summit Trail Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $539,000. Finally, Atria Investments Inc boosted its holdings in shares of Jazz Pharmaceuticals by 19.5% during the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock worth $336,000 after purchasing an additional 445 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Patricia Carr sold 4,813 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This represents a 36.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares of the company's stock, valued at approximately $11,368,526.40. This represents a 7.95% decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,236 shares of company stock worth $3,956,190 over the last three months. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock traded down $0.60 during midday trading on Friday, reaching $97.81. The company's stock had a trading volume of 1,217,193 shares, compared to its average volume of 833,461. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market cap of $6.03 billion, a PE ratio of 13.78, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The business has a 50-day moving average price of $118.96 and a 200-day moving average price of $122.19.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same period last year, the business earned $2.68 EPS. The company's revenue was down .5% compared to the same quarter last year. On average, sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Wall Street Analyst Weigh In

JAZZ has been the topic of several recent research reports. StockNews.com lowered shares of Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. Truist Financial raised their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their target price for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Finally, Barclays restated an "overweight" rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.